Bristol Myers Squibb (CGT Mfg)

Bothell, WA · Warren, NJ
Find alternatives to Bristol Myers Squibb (CGT Mfg) for CAR-T →
In-house manufacturer
586 confirmed programs · 226 sponsors · Last scored 2026-10-29
87.0
Signal Score
✓ FDA Inspections (8) ✓ Clinical Trials (586) ✓ SEC Filings (18) ○ Press ✓ EMA GMP (1) ✓ MHRA GMP (1) ✓ HC GMP (2)

Quick Facts: Bristol Myers Squibb (CGT Mfg)

Signal Score
87.0/100 (as of 2026-10-29)
Quality Compliance
97.2/100
Headquarters
Bothell, WA · Warren, NJ
Modalities
CAR-T, Cell Therapy
Active Programs
586 confirmed from ClinicalTrials.gov across 226 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Bristol Myers Squibb (CGT Mfg)

Manufactures Breyanzi and Abecma CAR-T therapies.

Signal Score & Pillar Breakdown

Quality Compliance 97.2
FDA Inspections8 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2026-04-28)
EMA GMP Certificates1 on record
MHRA GMP Certificates1 on record
Most Recent HC OutcomeCompliant · 2023-09-11
HC Attribution2 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations 95.2
586 active programs across 226 sponsors
Modalities: CAR-T, Cell Therapy
422 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
586 active programs across 226 sponsors · Modalities: CAR-T, Cell Therapy · 422 programs in advanced phases (Phase 2/3)
Programs 586
Sponsors226
ModalitiesCAR-T, Cell Therapy
586 active programs across 226 sponsors
Modalities: CAR-T, Cell Therapy
422 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07711483 GLORY: Glofit-GemOx With Liso-Cel For Lymphoma PHASE2 Not Yet Recruiting
NCT07680790 Study of Izalontamab Brengitecan (BMS-986507) in Combination... PHASE3 Not Yet Recruiting
NCT07573332 A Safety and Tolerability Study of CC- 97540 (BMS-086353) in... PHASE1 Not Yet Recruiting
NCT07335562 A Study to Compare the Efficacy and Safety of BMS-986353... PHASE3 Not Yet Recruiting
NCT07624513 D2 - Isa-Iber-VD Induction, Followed by Risk & Response... PHASE3 Not Yet Recruiting
NCT07680764 A Study To Assess the Safety, Tolerability, and Efficacy of... PHASE2 Recruiting
NCT07620574 Long-Term Extension Study for Participants Previously... PHASE3 Enrolling By Invitation
NCT07727668 Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior... EARLY_PHASE1 Not Yet Recruiting
NCT07544589 A Phase 1 Study Evaluating DISP-10 in Participants With... PHASE1 Recruiting
NCT07388277 CC-97540 in Patients With Antineutrophil Cytoplasmic... PHASE1/PHASE2 Active Not Recruiting
View all 586 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
18 SEC filings with industry mentions on record (shown, not scored)
SEC Filings18 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity 63.0
3 manufacturing sites
Sites: Bothell, WA, Warren, NJ, Devens, MA
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
3 manufacturing sites

Bristol Myers Squibb (CGT Mfg) FDA Inspection History

2026-04
2025-07
2025-07
2024-12
2024-09
2024-09
2023-09
2022-03
NAI VAI OAI
Date Site Type 483 citations posted Classification
2026-04-28
Bristol Myers Squibb
Princeton, New Jersey Facility-linked
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2025-07-18
Celgene Corporation
Summit, New Jersey Facility-linked
Human Cellular, Tissue, and Gene Therapies Not posted Voluntary Action Indicated (VAI)
2025-07-08
Bristol-Myers Squibb Company
Devens, Massachusetts Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-12-06
Celgene Corporation
Summit, New Jersey Facility-linked
Bioresearch Monitoring Yes Voluntary Action Indicated (VAI)
2024-09-24
Juno Therapeutics, Inc.
Bothell, Washington Facility-linked
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
2024-09-06
Celgene Corporation
Summit, New Jersey Facility-linked
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2023-09-20
Juno Therapeutics, Inc.
Bothell, Washington Facility-linked
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2022-03-18
Juno Therapeutics Inc
Seattle, Washington Company-level
Vaccines and Allergenic Products Not posted No Action Indicated (NAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Bristol Myers Squibb (CGT Mfg) FDA 483 Findings 3 observations · 2023-09-20 → 2023-09-20 ?

By subsystem

  • Documentation & Records 2 (66.7%)
  • Equipment & Facilities 1 (33.3%)

By severity

  • 2 — Minor: 3
  • Repeat observations: 0

Most severe findings

  • Minor (2) Equipment & Facilities 2023-09-20 21 CFR 211.67(b)
    Written procedures not established/followed

    "Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product."

  • Minor (2) Documentation & Records 2023-09-20 21 CFR 211.22(d)
    Procedures not in writing, fully followed

    "The responsibilities and procedures applicable to the quality control unit are not fully followed."

  • Minor (2) Documentation & Records 2023-09-20 21 CFR 211.113(b)
    Procedures for sterile drug products

    "Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed."

Bristol Myers Squibb (CGT Mfg) EMA GMP Compliance 1 certificates

2026-02
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
CRN00GYR3/IMP13128/00001 Bristol-Myers Squibb Services Unlimited Company Ireland 2026-02-10 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Bristol Myers Squibb (CGT Mfg) MHRA GMP Compliance 1 certificates

2014-08
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK GMP 14758 Insp GMP 14758/5575-0003[H] CELGENE CORPORATION 07901 2014-08-21 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

biologics, packaging/storage only · 1 site · own products, not contract-manufacturing evidence

  • Devens, United States · Bristol-Myers Squibb Company — biologics, packaging/storage only · valid to Sep 30, 2029

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. These approvals cover the company's own products; they are not evidence of contract manufacturing. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Clinical Activity 586 studies

NCT07711483 GLORY: Glofit-GemOx With Liso-Cel For Lymphoma PHASE2 Not Yet Recruiting NCT07680790 Study of Izalontamab Brengitecan (BMS-986507) in Combination With... PHASE3 Not Yet Recruiting NCT07573332 A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin... PHASE1 Not Yet Recruiting NCT07335562 A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene-... PHASE3 Not Yet Recruiting NCT07624513 D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted... PHASE3 Not Yet Recruiting NCT07680764 A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in... PHASE2 Recruiting NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an... PHASE3 Enrolling By Invitation NCT07727668 Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis... EARLY_PHASE1 Not Yet Recruiting NCT07544589 A Phase 1 Study Evaluating DISP-10 in Participants With Advanced... PHASE1 Recruiting NCT07388277 CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis PHASE1/PHASE2 Active Not Recruiting NCT07777120 Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma NA Active Not Recruiting NCT07361497 A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent... PHASE3 Recruiting NCT07361510 A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in... PHASE3 Recruiting NCT07333261 Study of BMS-986453 in Newly Diagnosed Multiple Myeloma PHASE1 Recruiting NCT07325136 A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in... PHASE1/PHASE2 Recruiting NCT07465029 A Study of Incidence, Treatment Patterns, and Outcomes in... NA Active Not Recruiting NCT07526961 Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy... NA Completed NCT07100080 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for... PHASE2/PHASE3 Recruiting NCT06855771 A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated... PHASE2 Recruiting NCT07018752 A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral... PHASE1/PHASE2 Recruiting
+ 566 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (100 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the group's board only shows its ~100 newest postings across all units, so we can't separate this business's roles. We'd rather show no number than one that isn't really this company's.
Source: bristolmyerssquibb.wd5.myworkdayjobs.com · Checked Nov 20, 2026

Financial Intelligence

10-Q 2026-07-30 1 keyword mentions
"rights to Abecma , a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
8-K 2026-07-30 0 keyword mentions
"Item 2.02 Results of Operations and Financial Condition: On July 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the second quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Other than the Earnings Press Release, the inform"
"Item 7.01 Regulation FD Disclosure: On July 30, 2026, the Company posted on its website at www.bms.com a presentation (the “Bristol Myers Presentation”) on certain financial and operating initiatives available for viewing during the Company’s conference call and webcast announcing its financial results for the second quarter of 2026 at 8:15 a.m. Eastern time. A copy of the Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit 99.2 to this Current Report on Form 8-K and in"
8-K 2026-05-08 0 keyword mentions
"Item 5.07: Submission of Matters to a Vote of Security Holders."
8-K 2026-04-30 0 keyword mentions
10-Q 2026-04-30 0 keyword mentions
10-K 2026-02-11 56 keyword mentions
"Our platforms are comprised of chemically-synthesized or small molecule drugs including protein degraders, drugs produced from biological processes, called “biologics”, ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics."
"CAR-T cell therapies are administered by intravenous infusion."
"Breyanzi ® Breyanzi (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL; relapsed or refractory MCL in patie"
8-K 2026-02-05 0 keyword mentions
8-K 2026-01-12 0 keyword mentions
8-K 2025-11-18 0 keyword mentions
8-K 2025-11-10 0 keyword mentions
8-K 2025-11-03 0 keyword mentions
10-Q 2025-10-30 8 keyword mentions
"The acquisition will provide BMS with full rights to OTX-201, a preclinical in vivo CAR T-cell therapy currently in IND-enabling studies for autoimmune disease."
"rights to Abecma , a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
"In October 2025, BMS entered into a definitive agreement to acquire Orbital Therapeutics, which will provide the Company with full rights to OTX-201, a preclinical in vivo CAR T-cell therapy currently in IND-enabling studies for autoimmune disease."
10-Q 2025-07-31 6 keyword mentions
"rights to Abecma , a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
"Breyanzi (lisocabtagene maraleucel) — a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL, and relapsed or refractory MCL in patients who "
"Abecma (idecabtagene vicleucel) — is a BCMA genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cyclic ADP ribose hydrolase monoclonal antibody."
10-Q 2025-04-24 9 keyword mentions
"rights to Abecma , a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
"Breyanzi (lisocabtagene maraleucel) — a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL, and relapsed or refractory MCL in patients who "
"revenues increased 133% during the first quarter of 2025 primarily due to higher demand enabled by expanded manufacturing capacity, new indication launches and higher average net selling prices."
10-K 2025-02-12 54 keyword mentions
"Our platforms are comprised of chemically-synthesized or small molecule drugs including protein degraders; drugs produced from biological processes, called “biologics”; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics."
"CAR-T cell therapies are administered by intravenous infusion."
"2 Breyanzi ® Breyanzi (lisocabtagene maraleucel) is a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL, and relapsed or refractory MCL in"
10-Q 2024-10-31 11 keyword mentions
"These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities."
"Our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases in the following core therapeutic areas: oncology and hematology with novel modalities in cell therapies, protein degraders, ADCs and radiopharmaceuticals; immunology with a focus on establishing new standards of care in pulmonology, rapidly advancing cell therapy into immunology diseases and transformational programs to control inflammation, reset immune memory and promote homeo"
"In addition, year-to-date, we have achieved significant advances in CAR-T cell therapy with the approval of Breyanzi in the U.S."
10-Q 2024-07-26 11 keyword mentions
"These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities."
"Our focus is on discovering, developing and delivering transformational medicines for patients facing serious diseases in the following five core therapeutic areas: (i) oncology with a priority in certain tumor types, including diversification beyond IO; (ii) hematology with opportunities to expand leadership position in multiple myeloma, as well as broaden our portfolio across leukemias, lymphomas and non-malignant hematologic diseases; (iii) immunology with a focus in dermatology, rheumatology"
"In 2024, we achieved significant advances in CAR-T cell therapy with the approval of Breyanzi in the U.S."
10-Q 2024-04-25 11 keyword mentions
"These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities."
"Our focus is on discovering, developing and delivering transformational medicines for patients facing serious diseases in the following five core therapeutic areas: (i) oncology with a priority in certain tumor types, including diversification beyond IO; (ii) hematology with opportunities to expand leadership position in multiple myeloma, as well as broaden our portfolio across leukemias, lymphomas and non-malignant hematologic diseases; (iii) immunology with a focus in dermatology, rheumatology"
"In 2024, we achieved significant advances in the CAR-T cell therapy arena with the approval of Abecma in the U.S."
Source: SEC EDGAR · Retrieved Nov 21, 2026

Frequently Asked Questions About Bristol Myers Squibb (CGT Mfg)

How many FDA inspections does Bristol Myers Squibb (CGT Mfg) have on record?
CDMO Signal tracks 8 FDA inspections for Bristol Myers Squibb (CGT Mfg), sourced from the FDA inspection database. See the full inspection history above.
Has Bristol Myers Squibb (CGT Mfg) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Bristol Myers Squibb (CGT Mfg).
Does Bristol Myers Squibb (CGT Mfg) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 1 EMA and 1 MHRA GMP certificates for Bristol Myers Squibb (CGT Mfg).
How many clinical programs is Bristol Myers Squibb (CGT Mfg) linked to?
Bristol Myers Squibb (CGT Mfg) is associated with 586 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Bristol Myers Squibb (CGT Mfg)'s CDMO Signal Score?
Bristol Myers Squibb (CGT Mfg) has a Signal Score of 87/100, based on quality, operations, financial stability, and capacity data.
Evaluating Bristol Myers Squibb (CGT Mfg) for a manufacturing program?
Use the free AI matchmaker to compare Bristol Myers Squibb (CGT Mfg) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
RoslinCT
Edinburgh, UK · Hopkinton, MA
Signal Score: 79.3
CAR-T, Cell Therapy, iPSC, Gene Editing

Compare Bristol Myers Squibb (CGT Mfg) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Bristol Myers Squibb (CGT Mfg)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.